An article on ImmunoGen Inc. in the Oct. 18, 2000, issue of BioWorld Today misstated the date of an agreement with SmithKline Beecham Corp plc, of London, which was entered in February 1999. Also, a $5 million technology access fee from Abgenix Inc. does not include potential milestone payments and royalties, as might have been implied.

Editor's Note: The corrections already were made in BioWorld Online.

No Comments